Effect of Zoledronic Acid in Hepatic Osteodystrophy: A Double-Blinded Placebo-Controlled Trial.

In a study examining the effect of ZA on bone microarchitecture in male participants with non-metastatic prostate cancer undergoing androgen deprivation therapy, there was no significant improvement in bone microarchitecture in the ZA arm despite an increase in BMD.[ 27 ] This phenomenon can be explained by the failure of ZA to completely suppress imbalanced bone remodelling, together with its inability to penetrate and distribute in sufficient quantity into deeper cortical bone tissue.[ 27 ] Effect of ZA on BTMs β-CTX levels showed a decreasing trend in the ZA arm (median percentage decrease of 43.22 at 12 months), while in the placebo arm, they initially decreased at 6 months (median percentage decrease of 10.3) but showed an increasing trend at 12 months (median percentage increase of 10.47).

also in 47,180 other papers

in sufficient quantity into deeper cortical bone tissue.[ 27 ] Effect of ZA on BTMs β-CTX levels showed a decreasing trend in the ZA arm (median percentage decrease of 43.22 at 12 months), while in the placebo arm, they initially decreased at 6 months (median percentage decrease of 10.3) but showed an increasing trend at 12 months (median percentage increase of 10.47).

also in 63,971 other papers